Literature DB >> 22517797

Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.

John J Strouse1, Matthew M Heeney.   

Abstract

Hydroxyurea is the only approved medication in the United States for the treatment of sickle cell anemia (HbSS) and is widely used in children despite an indication limited to adults. We review the evidence of efficacy and safety in children with reference to pivotal adult studies. This evidence and expert opinion form the basis for recommended guidelines for the use of hydroxyurea in children including indications, dosing, therapeutic and safety monitoring, and interventions to improve adherence. However, there are substantial gaps in our knowledge to be addressed by on-going and planned studies in children.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22517797      PMCID： PMC3374046          DOI： 10.1002/pbc.24178

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  42 in total

1.  Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease.

Authors:  Mark T Gladwin; James H Shelhamer; Frederick P Ognibene; Margaret E Pease-Fye; James S Nichols; Beth Link; Daksesh B Patel; Marcin A Jankowski; Lewis K Pannell; Alan N Schechter; Griffin P Rodgers
Journal:  Br J Haematol       Date:  2002-02       Impact factor: 6.998

2.  A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.

Authors:  W C Wang; L W Wynn; Z R Rogers; J P Scott; P A Lane; R E Ware
Journal:  J Pediatr       Date:  2001-12       Impact factor: 4.406

Review 3.  Sociobehavioral determinants of compliance with health and medical care recommendations.

Authors:  M H Becker; L A Maiman
Journal:  Med Care       Date:  1975-01       Impact factor: 2.983

4.  Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.

Authors:  Russell E Ware; William H Schultz; Nancy Yovetich; Nicole A Mortier; Ofelia Alvarez; Lee Hilliard; Rathi V Iyer; Scott T Miller; Zora R Rogers; J Paul Scott; Myron Waclawiw; Ronald W Helms
Journal:  Pediatr Blood Cancer       Date:  2011-08-08       Impact factor: 3.167

5.  Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure.

Authors:  Patrick T McGann; Thad A Howard; Jonathan M Flanagan; Jill M Lahti; Russell E Ware
Journal:  Br J Haematol       Date:  2011-05-04       Impact factor: 6.998

6.  Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia.

Authors:  Malika Benkerrou; Charlotte Delarche; Lamia Brahimi; Michèle Fay; Etienne Vilmer; Jacques Elion; Marie-Anne Gougerot-Pocidalo; Carole Elbim
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

7.  Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.

Authors:  Russell E Ware; Sherri A Zimmerman; Pamela B Sylvestre; Nicole A Mortier; Jacqueline S Davis; William R Treem; William H Schultz
Journal:  J Pediatr       Date:  2004-09       Impact factor: 4.406

8.  Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Authors:  Sherri A Zimmerman; William H Schultz; Jacqueline S Davis; Chrisley V Pickens; Nicole A Mortier; Thad A Howard; Russell E Ware
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

9.  Chemical and functional analysis of hydroxyurea oral solutions.

Authors:  Matthew M Heeney; Matthew R Whorton; Thad A Howard; Christina A Johnson; Russell E Ware
Journal:  J Pediatr Hematol Oncol       Date:  2004-03       Impact factor: 1.289

10.  Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.

Authors:  O S Platt; S H Orkin; G Dover; G P Beardsley; B Miller; D G Nathan
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808
View more
  29 in total

1.  Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.

Authors:  Winfred C Wang; Suzette O Oyeku; Zhaoyu Luo; Sheree L Boulet; Scott T Miller; James F Casella; Billie Fish; Bruce W Thompson; Scott D Grosse
Journal:  Pediatrics       Date:  2013-09-02       Impact factor: 7.124

2.  Do difficulties in swallowing medication impede the use of hydroxyurea in children?

Authors:  ElShadey Bekele; Courtney D Thornburg; Amanda M Brandow; Mukta Sharma; Arlene M Smaldone; Zhezhen Jin; Nancy S Green
Journal:  Pediatr Blood Cancer       Date:  2014-04-17       Impact factor: 3.167

3.  The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.

Authors:  Shuaiying Cui; Kim-Chew Lim; Lihong Shi; Mary Lee; Natee Jearawiriyapaisarn; Greggory Myers; Andrew Campbell; David Harro; Shigeki Iwase; Raymond C Trievel; Angela Rivers; Joseph DeSimone; Donald Lavelle; Yogen Saunthararajah; James Douglas Engel
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

4.  Relationship of Omega-3 fatty acids DHA and EPA with the inflammatory biomarker hs-CRP in children with sickle cell anemia.

Authors:  B N Yamaja Setty; Suhita Gayen Betal; Robin E Miller; Dawn S Brown; Maureen Meier; Michele Cahill; Norma B Lerner; Nataly Apollonsky; Marie J Stuart
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2019-05-10       Impact factor: 4.006

5.  Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study.

Authors:  Jason R Hodges; Shannon M Phillips; Sarah Norell; Chinonyelum Nwosu; Hamda Khan; Lingzi Luo; Sherif M Badawy; Allison King; Paula Tanabe; Marsha Treadwell; Lucia Rojas Smith; Cecelia Calhoun; Jane S Hankins; Jerlym Porter
Journal:  Blood Adv       Date:  2020-09-22

6.  Examining Biopsychosocial Factors in Relation to Multiple Pain Features in Pediatric Sickle Cell Disease.

Authors:  Alyssa M Schlenz; Jeffrey Schatz; Carla W Roberts
Journal:  J Pediatr Psychol       Date:  2016-02-10

Review 7.  Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.

Authors:  Wai Cheng Foong; Jacqueline J Ho; C Khai Loh; Vip Viprakasit
Journal:  Cochrane Database Syst Rev       Date:  2016-10-18

Review 8.  Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine.

Authors:  Min Dong; Patrick T McGann
Journal:  Clin Pharmacol Ther       Date:  2020-10-08       Impact factor: 6.875

9.  Cistanche deserticola decoction alleviates the testicular toxicity induced by hydroxyurea in male mice.

Authors:  Li Gu; Wen-Ting Xiong; Chao Wang; Hong-Xia Sun; Guo-Fu Li; Xin Liu
Journal:  Asian J Androl       Date:  2013-07-01       Impact factor: 3.285

10.  Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: a feasibility study.

Authors:  Susumu Inoue; Gergana Kodjebacheva; Tammy Scherrer; Gary Rice; Matthew Grigorian; Jeremy Blankenship; Nkechi Onwuzurike
Journal:  Int J Hematol       Date:  2016-05-25       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.